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Review Series: New Features of Systemic Vasculitides
Direct and Indirect Pathogenic Roles
of Autoantibodies in Systemic
Autoimmune Diseases
Takao Fujii1
ABSTRACT
Autoantibody (autoAb) production in patients with systemic autoimmune diseases is a hallmark of disease en-
tity, activity and prognosis. Although a large number of autoAbs have been discovered to date, there is a limited
number of autoAbs whose pathogenic roles have been clearly determined. However, intriguing evidence has
recently been provided of possible pathogenic roles for anti-neutrophil cytoplasmic Abs (ANCAs) against
myeloperoxidase (MPO) in ANCA-associated vasculitides (AAV) and for anti-citrullinated protein Abs (ACPAs)
in rheumatoid arthritis (RA). Of note, these autoAbs are thought to display both direct and indirect effects on or-
gan failure. Additionally, some autoAbs have been reported to play pathogenic roles in brain damage in pa-
tients with neuropsychiatric systemic lupus erythematosus (NPSLE), which is one of the most refractory auto-
immune disorders. Thus the binding of autoAbs to a certain sequence of the N-methyl-D-aspartate receptor
subunit NR2 (anti-NR2 Abs) may directly induce hippocampal neuronal injury. On the other hand, anti-U1 ribo-
nucleoprotein (RNP) Abs might be pathogenic by inducing neurotoxic inflammatory mediators intrathecally.
Such autoAb measurements are also clinically meaningful for treatment selection.
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INTRODUCTION
Autoantibodies (AutoAbs) directed against various
human antigens are found in sera from patients with
systemic autoimmune diseases. AutoAb production is
one of the most important immunological disorders
in systemic autoimmune diseases and autoAb meas-
urements also have clinical significance.1 First,
marker Abs that are highly specific for a disease have
a diagnostic value. In most of the classification crite-
ria for systemic rheumatic diseases, autoAbs are in-
cluded as an important item.2-4 Second, a certain sub-
set of autoAbs is closely associated with severe or
life-threatening manifestation of specific disease. In
such cases, the presence of autoAbs in serum is infor-
mative for determination of treatment. Third, some
autoAbs are correlated to disease activity. Sequential
determination of such autoAb titers is helpful for
evaluation of treatment efficacy. To date, there have
been a huge number of reports suggesting the clini-
cal significance of autoAbs in systemic autoimmune
diseases, and techniques for autoAb detection, which
have been proved to be clinically meaningful, have
been developed. Thus, autoAb tests are indispensable
in clinical practice for autoimmune diseases and inter-
national recommendations for assessing anti-nuclear
antibodies (ANA) have been published.5
However, for the majority of autoAbs, it is still un-
clear whether they are truly involved in the etiopatho-
genesis of systemic autoimmune diseases or not.
Neonatal lupus syndrome may be a good example to
cite in this respect, as it is a disease in which it is sug-
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gested that anti-RoSS-A Abs can be pathogenic un-
der certain conditions, but the detailed mechanism
has not been determined. Drachman suggested a set
of 5 criteria that a putative autoAb must fulfil in order
to be considered pathogenic6: 1) Abs are present in
patients with the disease, 2) Abs interact with the tar-
get antigen, 3) passive transfer of Ab reproduces fea-
tures of the disease, 4) immunization with antigens
produces a model disease and 5) reduction in Ab lev-
els ameliorates the disease. In other words, both in
vitro and in vivo experiments in addition to clinical
evidence are required for confirmation of the patho-
genicity of autoAbs.
When organ and tissue damage is induced by IgG-
Abs, two different possibilities may be supposed.
First, the Abs might bind functional autoantigens
(e.g., a receptor) that are expressed on the target tis-
sues and directly suppress these autoantigens or in-
duce an abnormal stimulation (direct pathogenic
role). As an example, in patients with Basedow’s dis-
ease, Abs against thyroid stimulating hormone recep-
tor increase secretion of thyroid hormone. Second,
recognition of an autoAb-included immune complex
(IC) by FcγR could activate inflammatory mediators
(e.g., cytokines) or the complement system, which
can induce systemic or local tissue injury (indirect
pathogenic role). Under such conditions, the pres-
ence of the autoAb inside the target tissue is not al-
ways evident.
In this review, we focus on three systemic autoim-
mune diseases including vasculitis. The autoAbs
closely associated with these diseases are discussed
from the point of view of direct and indirect patho-
genic roles.
ANCA-ASSOCIATED VASCULITIDES
Anti-neutrophil cytoplasmic antibody (ANCA)-asso-
ciated vasculitides (AAV) comprise granulomatosis
with polyangiitis (GPA, formerly Wegener’s granulo-
matosis), microscopic polyangiitis (MPA), and
eosinophilic granulomatosis with polyangiitis (EGPA,
formerly Churg-Strauss syndrome). The major target
antigens of ANCAs are proteinase 3 (PR3) and
myeloperoxidase (MPO). GPA is usually associated
with PR3-ANCA, whereas MPA and GPA are associ-
ated with MPO-ANCA. Detection of ANCAs in the
sera of patients with systemic vasculitis helps to con-
firm their diagnosis. Whereas ANCAs disappear dur-
ing inactive disease or remission, an increased titer of
ANCA is related to the active disease or to relapse.
More than 10 UmL of PR3-ANCA at 24 months after
the initiation of treatment was predictive of relapse
within 5 years.7 Thus, ANCA titers are closely associ-
ated with AAV-activity. A report of neonatal vasculitis
occurring in a child born from a mother with AAV
suggests a pathogenic role for MPO-ANCA.8 There-
fore, transient but severe manifestations specific to
vasculitis syndrome in the neonate might be caused
by transplacental transfer of MPO-ANCA. However, a
healthy newborn despite transplacental transfer of
MPO-ANCA has been reported.9 The latter observa-
tion could suggest that MPO-ANCA is not always
pathogenic. Epitope specificity (e.g., aa447-459) rec-
ognized by MPO-ANCA may be associated with
pathogenesis.10
Relapses in AAV occur far more frequently in pa-
tients with PR3-ANCA than those with MPO-ANCA ir-
respective of the associated disease. In addition, PR3-
ANCA is associated with granulomatous inflamma-
tion and faster decline in kidney function.11 These
clinical differences in relation to the antigenic speci-
ficity of ANCAs might be explained by genetic back-
grounds.12
Whereas the mechanisms of PR3-ANCA-mediated
pathogenesis are not well understood, MPO-ANCA is
the autoAbs, which appear to fulfill Drachman’s crite-
ria and has pathogenicity. The most important char-
acteristics of AAV are pauci-immune necrotizing
small-vessel vasculitis and glomerulonephritis, com-
bined with granulomatous inflammation particularly
in GPA and EGPA. An animal model of MPO-ANCA-
associated AAV, which was made by immunization of
MPO-deficient mice with mouse MPO, was devel-
oped by Xiao et al..13 These mice developed an im-
mune response to mouse MPO. Subsequently,
splenocytes from these mice were transferred into
immunodeficient mice. These recipient mice devel-
oped pauci-immune necrotizing crescent glomeru-
lonephritis and systemic necrotizing small vessel vas-
culitis including hemorrhagic pulmonary capillaritis.
Neutrophils as well as the presence of MPO were re-
quirements for the induction of lesions in this animal
model.14,15 Thus, MPO-ANCAs have the capacity to
further activate primed neutrophils to release prote-
olytic enzymes (Fig. 1).11 Priming of neutrophils was
induced by low-dose TNF-α, but also can be mediated
by other inflammatory mediators (IMs) such as IL-1,
IL-18, and the complement degradation product
C5a.16 In order to activate neutrophils, ANCAs not
only have to bind to surface-expressed PR3,17 but also
have to interact with receptors for the Fc part of the
IgG molecule (FcγR),18 which are present on the neu-
trophils. Thus, the pathogenic roles of MPO-ANCA in
AAV are mainly explained by indirect rather than by
direct effects on small vessel endothelial cells.
A more indirect effect of ANCA has been reported.
ANCA can induce the release of microparticles from
primed neutrophils followed by binding of these mi-
croparticles to endothelial cells.19 After binding, these
endothelial cells show increased expression of adhe-
sion molecules, release of IL-6 and IL-8 and produc-
tion of reactive oxygen species, which can induce vas-
cular permeability.
Interestingly, it has also been reported that MPO-
ANCA directly upregulates adhesion molecule ex-
pression in mouse glomerular endothelial cells.20 The
Direct and Indirect AutoAb Pathogenicity
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Fig.　1　Indirect pathogenic effects of anti-neutrophil cytoplasmic antibodies (ANCAs) on 
small vessels. ANCA activates neutrophils by binding to cell surface antigens expressed 
on cytokine (e.g., TNF-α)-primed neutrophils. As a result, neutrophil degranulation occurs 
and reactive oxygen species (ROS) are produced. The consequent release of proteolytic 
enzymes leads to capillaritis. The alternative pathway of complement activation plays a 
role as an amplifi cation loop of the infl ammatory response. ICAM-1, intercellular adhesion 
molecule 1; C5aR, C5a receptor. Reproduced with permission and modifi ed from: Kallen-
berg CGM, et al. Pathogenesis of ANCA-associated vasculitis: new possibilities for inter-
vention. Am J Kidney Dis 2013; 62: 1176-87.
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passive transfer of MPO-ANCA to normal mice leads
to glomerular damage with neutrophil infiltration.13
This phenomenon might be the result of cross-
reactivity between MPO-ANCAs and anti-moesin
Abs.20 By direct binding to moesin, which is a mem-
ber of the EzrinRadixinMoesin (ERM) family pro-
teins that act as links between the plasma membrane
and the actin cytoskeleton, MPO-ANCA leads to an
upregulation of endothelial proteins such as intercel-
lular adhesion molecule, vascular cell adhesion
molecule-1 and E-selectin. Consequently, anti-moesin
Abs andor MPO-ANCA stimulate the production of
keratinocyte-derived chemokine and macrophage in-
flammatory protein-2 by glomerular endothelial cells.
These data strongly suggest that MPO-ANCA can di-
rectly contribute to the pathogenesis of glomeru-
lonephritis through more than one mechanism.21
RHEUMATOID ARTHRITIS
Rheumatoid arthritis (RA) is a systemic autoimmune
disease that is characterized by persistent, destruc-
tive articular damage and by anti-citrullinated protein
antibodies (ACPAs).22 The 2010 criteria of the Ameri-
can College of RheumatologyEuropean League
Against Rheumatism2 includes both ACPA and rheu-
matoid factor (RF) as a single “serology” criterion. In
patients with arthralgia, however, the presence of
ACPA, but not of RF or of a shared epitope,23 predicts
subsequent arthritis development. When RA patients
were divided into 3 groups (ACPA-positiveRF-
negative, ACPA-negativeRF-positive, and ACPA-
negativeRF-negative) that were compared with nor-
mal healthy controls, the level of C-terminal cleavage
products for collagen type I (CTXI), which is a
marker of bone resorption, was significantly higher in
the ACPA-positiveRF negative RA patients than in all
other groups.24 In this study, ACPA-positiveRF-
positive RA patients were excluded, because head-to-
head comparison of arthritogenic effects between by
both autoAbs was intended. Also, ACPA titers were
significantly correlated with CTXI levels. Another
study examined whether Abs against mutated citrulli-
nated vimentin (MCV) can induce osteoclastogenesis
and bone resorption. In in vitro experiments, MCV-
ACPA induces MCSFRANKL-mediated osteoclast-
genesis. Of note, not only the whole IgG, but also the
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Fig.　2　Indirect pathogenic effects of anti-citrullinated protein antibodies (ACPA) on rheumatoid 
synovitis (RA cycle). Infl ammation of the joint leads to infi ltration of immune cells (step 1), which 
contain peptidylarginine deiminase (PAD) enzymes. PAD activation induces the citrullination of 
target proteins (step 2). In a small percentage of individuals, citrullinated proteins are exposed to 
the immune system, which elicits an immune response and anti-citrullinated protein antibodies 
(ACPA) production (step 3), resulting in immune complex formation (step 4), followed by proin-
fl ammatory cytokine activation (step 5). Subsequently, new infl ammatory cells are developed and 
the vicious RA cycle continues. Adapted from: van Venrooij WJ, et al. An important step towards 
completing the rheumatoid arthritis cycle. Arthritis Res Ther 2008; 10: 117.
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Fab fragment of MCV-ACPA can induce similar bone
resorption, suggesting that the possibility that indi-
rect osteoclastogenesis occurs solely through an Fc-
mediated effect was excluded. MCV-ACPA was also
proven to induce systemic bone loss and osteoclast
formation in vivo, because Rag1−− mice challenged
with MCV-ACPA showed a significant reduction in
trabecular bone.24
On the other hand, in an in vitro model, ACPA-
containing ICs induced tumor necrosis factor secre-
tion by human macrophages via engagement of
FcγRIIa at the surface of these cells.25 ACPAs also ac-
tivate the complement system in vitro via classical
and alternative pathways. Previous reports clearly
showed that citrullination boosts the local inflamma-
tory response at sites of damage or inflammation, in-
dicating indirect pathogenic effects of ACPAs.26 Un-
like RF, ACPA production is mediated by autoreac-
tive T cells.27,28 Based on these data, van Venrooij et
al. suggested a vicious cycle in patients with RA (‘The
RA cycle’), in which ACPA-ICs have a central role in
RA etiopathogenesis by continuously promoting the
production of inflammatory mediators (Fig. 2).29
Clinical research clearly shows that the presence of
ACPA is associated with greater radiological joint
damage in patients with RA. Additionally, the Abs
against certain subsets of citrullinated proteins (e.g.,
fibrinogen or vimentin) may meet Drachman’s crite-
ria and have arthritogenic effects in patients with RA.
NEUROPSYCHIATRIC SYSTEMIC LUPUS
ERYTHEMATOSUS
Systemic lupus erythematosus (SLE) is a chronic
multisystem autoimmune disease, and neuropsychiat-
ric SLE (NPSLE) is a severe life-threatening condi-
tion. To date, it has been reported that a certain ANA
subset is relevant to central NPSLE. Serum anti-
ribosomal P Abs are definitely a useful marker for
NPSLE30 and some reports have shown that anti-
ribosomal P Abs in cerebrospinal fluids (CSF) are
linked to central NPSLE.31,32 Regarding the patho-
genic roles of anti-ribosomal P Abs, direct effects on
Th1 cells33 and neuroblastoma cells34 were demon-
strated. Ribosomal P protein may be expressed on
Direct and Indirect AutoAb Pathogenicity
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Fig.　3　Anti-nuclear antibodies in CSF may be an inducer of neurotoxic infl ammatory mediators. Cerebrospinal fl uid (CSF) from 
neuropsychiatric systemic lupus erythematosus (NPSLE) patients induces neurotoxic infl ammatory mediators (IMs). NPSLE 
CSF was incubated with unprimed PBMCs in the presence (+) or absence (-) of nuclear antigens. Cytokines (A) and chemo-
kines (B) were quantifi ed after 24 hours using a multiplex assay. **P < 0.01, ***P < 0.001. n.s., not signifi cant; Ag, autoantigen; 
IP-10, Interferon-inducible protein-10; MCP-1, monocyte chemotactic protein-1; MIP-1α, macrophage infl ammatory protein-1α. 
(A) (B) Adapted with permission from: Santer DM, et al. Potent induction of IFN-α and chemokines by autoantibodies in the ce-
rebrospinal fl uid of patients with neuropsychiatric lupus. J Immunol 2009; 182: 1192-201 (reference 36). Copyright 2009. The 
American Association of Immunologists, Inc. (C) We determined anti-U1 ribonucleoprotein (RNP) Abs in the CSF from NPSLE 
patients. The presence of anti-U1RNP Abs in CSF is associated with an increased concentration of CSF IFN-α, which is neurito-
genic. *P < 0.05.
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the neuronal cell surface and anti-ribosomal P Abs
can directly contribute to neuronal death.35 Alterna-
tively, a close correlation of anti-ribosomal P Abs to
CSF IMs was strongly suggested in an in vitro
study.35,36
Kowal et al. reported that a certain anti-dsDNA Ab
subset in CSF, which cross-reacts with the NR2 gluta-
mate receptor, causes apoptotic neuronal death in the
mouse hippocampus.37 In NPSLE, Abs that bind to a
specific sequence of the N-methyl-D-aspartate recep-
tor subunit NR2 (anti-NR2 Abs) may be the most es-
tablished neurotoxic autoAbs and may meet Drach-
man’s criteria. Anti-NR2 Abs, which cross-react anti-
DNA Abs, can inhibit excitatory synaptic transmis-
sions in the central nervous system.38 In a mouse
model, after a breach in blood brain barrier (BBB) in-
tegrity induced by LPS, anti-NR2 Abs that are pas-
sively transferred directly attack neurotransmitters.
Also in human lupus, anti-NR2 Abs in CSF, but not in
serum, were shown to be involved in diffuse central
NPSLE.39-41 A BBB injury results in an anti-NR2 Ab-
mediated severe psychiatric disorder41 and an attack
of serum anti-NR2 Abs on endothelial cells may trig-
ger BBB injury.42
On the other hand, our cohort shows that anti-U1
ribonucleoprotein (RNP) Abs are more frequently ob-
served than anti-DNA Abs in the sera of patients with
NPSLE. Okada et al. previously reported that 13 of 14
patients (7 SLE, 5 mixed connective tissue disease
(MCTD) or overlap syndrome, 1 undifferentiated
CTD and 1 Sjögren’s syndrome) with aseptic menin-
gitis attributed to CTD had serum anti-U1 RNP Abs.43
Recently, by using an RNA-immunoprecipitation as-
say (RNA-IPP), we found that anti-U1RNP Abs in CSF
could be a useful biomarker of primary NPSLE.44,45
Compared with ELISA, RNA-IPP is a more sensitive
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and specific immunological method for detection of
anti-RNA binding protein (RBP) Abs such as anti-U1
RNP, especially Abs against the native form of RBP.46
Because less than 20 μL of sample is enough for as-
say, RNA-IPP is also more suitable than ELISA for de-
tection of anti-RBP Abs in CSF, which usually cannot
be obtained in large amounts from patients. However,
how CSF anti-U1RNP Abs correlate to NPSLE patho-
genesis remains unclear. In addition to autoAbs, IMs
(cytokines and chemokines) have been found in the
CSF of NPSLE patients.47,48 Previous reports showed
that the levels of IFN-α,49 IFN-γ-inducible protein
(IP)-10,50 IL-8,51 monocyte chemotactic protein
(MCP)-152 and fractalkine (CX3CL1)53 in CSF are sig-
nificantly higher in NPSLE than in non-NPSLE pa-
tients. IFN-α production in SLE is caused, at least
partially, by autoAbs binding to RNP particles re-
leased from dead or dying cells.54,55 Interestingly,
there was no significant difference in CSF IFN-α lev-
els between serum anti-U1RNP Ab-positive patients
and controls. However, the CSF IFN-α level was sig-
nificantly elevated in patients whose CSF was positive
for anti-U1RNP Abs (Fig. 3).56 Fragoso-Loyo et al. re-
ported that CSF IFN-α was not a useful biomarker of
central NPSLE.57 Our data indicated that no elevation
of CSF IFN-α levels occurred in patients without CSF
anti-U1RNP Abs and that an increased CSF IM levels
may depend on the specificity of CSF autoAbs. Al-
though there was no significant association of serum
or CSF anti-U1RNP Ab positivity with NPSLE forms
in our patients, anti-U1RNP Ab-IC might have an indi-
rect effect on brain tissue as a neurotoxic IM-
inducer.36
CONCLUSION
In discussing the pathogenic roles of autoAbs, espe-
cially those in systemic autoimmune diseases, indi-
rect effects of autoAbs on the development of disease-
specific organ damage should be considered. Even if
autoAbs fail to directly react with antigens expressed
on the target organ, it is possible that autoAbs that
are closely associated with clinical manifestations are
involved in the disease etiopathogenesis. For investi-
gation of more effective treatment targets of systemic
autoimmune diseases, both future clinical and basic
research of autoAbs are warranted.
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